X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs BIOCON LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA BIOCON LTD TORRENT PHARMA/
BIOCON LTD
 
P/E (TTM) x 25.9 36.6 70.7% View Chart
P/BV x 6.3 4.9 130.2% View Chart
Dividend Yield % 3.2 1.5 207.4%  

Financials

 TORRENT PHARMA   BIOCON LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
BIOCON LTD
Mar-16
TORRENT PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,720496 347.0%   
Low Rs1,134397 285.9%   
Sales per share (Unadj.) Rs394.5174.3 226.4%  
Earnings per share (Unadj.) Rs101.844.8 227.2%  
Cash flow per share (Unadj.) Rs116.356.9 204.4%  
Dividends per share (Unadj.) Rs40.005.00 800.0%  
Dividend yield (eoy) %2.81.1 250.1%  
Book value per share (Unadj.) Rs200.3202.8 98.8%  
Shares outstanding (eoy) m169.22200.00 84.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.62.6 141.3%   
Avg P/E ratio x14.010.0 140.8%  
P/CF ratio (eoy) x12.37.8 156.5%  
Price / Book Value ratio x7.12.2 323.8%  
Dividend payout %39.311.2 352.2%   
Avg Mkt Cap Rs m241,43589,220 270.6%   
No. of employees `00010.94.4 246.7%   
Total wages/salary Rs m8,5596,363 134.5%   
Avg. sales/employee Rs Th6,129.67,894.5 77.6%   
Avg. wages/employee Rs Th785.81,441.2 54.5%   
Avg. net profit/employee Rs Th1,581.32,029.7 77.9%   
INCOME DATA
Net Sales Rs m66,76434,854 191.6%  
Other income Rs m2,156845 255.2%   
Total revenues Rs m68,92035,699 193.1%   
Gross profit Rs m27,2048,200 331.8%  
Depreciation Rs m2,4612,423 101.6%   
Interest Rs m1,859102 1,822.3%   
Profit before tax Rs m25,0416,520 384.1%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1,4035,754 -24.4%   
Tax Rs m6,4142,569 249.7%   
Profit after tax Rs m17,2248,961 192.2%  
Gross profit margin %40.723.5 173.2%  
Effective tax rate %25.639.4 65.0%   
Net profit margin %25.825.7 100.3%  
BALANCE SHEET DATA
Current assets Rs m46,62239,932 116.8%   
Current liabilities Rs m32,84316,276 201.8%   
Net working cap to sales %20.667.9 30.4%  
Current ratio x1.42.5 57.9%  
Inventory Days Days7454 138.6%  
Debtors Days Days7986 91.7%  
Net fixed assets Rs m39,02939,101 99.8%   
Share capital Rs m8461,000 84.6%   
"Free" reserves Rs m31,40038,591 81.4%   
Net worth Rs m33,89040,556 83.6%   
Long term debt Rs m18,63720,724 89.9%   
Total assets Rs m90,13684,816 106.3%  
Interest coverage x14.564.9 22.3%   
Debt to equity ratio x0.50.5 107.6%  
Sales to assets ratio x0.70.4 180.2%   
Return on assets %21.210.7 198.1%  
Return on equity %50.822.1 230.0%  
Return on capital %48.519.0 255.7%  
Exports to sales %43.330.7 140.9%   
Imports to sales %6.920.4 33.7%   
Exports (fob) Rs m28,93410,717 270.0%   
Imports (cif) Rs m4,5847,105 64.5%   
Fx inflow Rs m29,18511,789 247.6%   
Fx outflow Rs m6,0218,393 71.7%   
Net fx Rs m23,1653,396 682.1%   
CASH FLOW
From Operations Rs m27,1325,264 515.4%  
From Investments Rs m-7,014-9,540 73.5%  
From Financial Activity Rs m-14,35210,867 -132.1%  
Net Cashflow Rs m5,7676,591 87.5%  

Share Holding

Indian Promoters % 71.5 40.4 177.0%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 7.0 8.4 83.6%  
FIIs % 12.6 10.7 117.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 19.9 44.2%  
Shareholders   26,511 109,995 24.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   STRIDES SHASUN LTD  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS